Shares of ADMA Biologics Inc (NASDAQ:ADMA) have earned a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and two have issued a strong buy rating on the company. ADMA Biologics’ rating score has improved by 20.4% from three months ago as a result of various analysts’ upgrades and downgrades.

Analysts have set a 12-month consensus target price of $8.88 for the company and are forecasting that the company will post ($0.51) earnings per share for the current quarter, according to Zacks. Zacks has also assigned ADMA Biologics an industry rank of 111 out of 265 based on the ratings given to its competitors.

ADMA has been the topic of several research reports. ValuEngine downgraded shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Raymond James Financial, Inc. raised shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research note on Tuesday, November 14th.

In other news, Director Eric I. Richman bought 25,000 shares of the business’s stock in a transaction dated Thursday, November 9th. The shares were purchased at an average price of $2.15 per share, for a total transaction of $53,750.00. Following the completion of the acquisition, the director now owns 31,300 shares of the company’s stock, valued at $67,295. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Adam S. Grossman bought 485,000 shares of the business’s stock in a transaction dated Thursday, November 9th. The stock was purchased at an average price of $2.15 per share, for a total transaction of $1,042,750.00. The disclosure for this purchase can be found here. Insiders bought 526,500 shares of company stock worth $1,131,975 in the last 90 days. Company insiders own 60.44% of the company’s stock.

A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC raised its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 565,000 shares of the biotechnology company’s stock after buying an additional 415,000 shares during the quarter. Iguana Healthcare Management LLC owned about 2.19% of ADMA Biologics worth $1,740,000 at the end of the most recent quarter. Institutional investors own 33.18% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/21/analysts-set-8-88-price-target-for-adma-biologics-inc-adma.html.

ADMA Biologics (NASDAQ:ADMA) opened at $2.87 on Tuesday. ADMA Biologics has a one year low of $2.01 and a one year high of $6.10. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.